Prism Medico reports net profit of ₹31.84 lakh in FY26

1 min read     Updated on 28 May 2026, 07:18 PM
scanx
Reviewed by
Riya DScanX News Team
AI Summary

Prism Medico and Pharmacy Limited reported a net profit of ₹31.84 lakh for the financial year ended March 31, 2026, reversing the net loss of ₹4.87 lakh recorded in the previous year. Revenue from operations surged to ₹244.34 lakh in FY26 from ₹63.19 lakh in FY25, driven primarily by the sale of pharmaceutical products. The board approved the audited standalone financial results at its meeting held on May 28, 2026. The statutory auditors, Garg Mendiratta & Associates, issued an unmodified opinion on the financial statements.

powered bylight_fuzz_icon
41095790

*this image is generated using AI for illustrative purposes only.

Prism Medico and Pharmacy Limited reported a net profit of ₹31.84 lakh for the financial year ended March 31, 2026, reversing the net loss of ₹4.87 lakh recorded in the previous year. Revenue from operations surged to ₹244.34 lakh in FY26 from ₹63.19 lakh in FY25, driven primarily by the sale of pharmaceutical products. The board approved the audited standalone financial results at its meeting held on May 28, 2026, at the registered office in Kala Amb, Himachal Pradesh.

Financial Performance

The company’s total income for FY26 stood at ₹246.95 lakh, a significant increase from ₹64.84 lakh in the previous year. Total expenses for the period were ₹203.99 lakh, up from ₹71.42 lakh in FY25. The profit before tax for the year was ₹42.96 lakh, compared to a loss before tax of ₹6.58 lakh in the preceding year. The board reviewed the performance for the quarter and financial year ended March 31, 2026, along with the Auditors Report.

Metric FY26 (₹ in Lakhs) FY25 (₹ in Lakhs)
Revenue from Operations 244.34 63.19
Total Income 246.95 64.84
Total Expenses 203.99 71.42
Profit Before Tax 42.96 (6.58)
Net Profit 31.84 (4.87)

Auditor and Compliance Details

The statutory auditors, Garg Mendiratta & Associates, issued an unmodified opinion on the financial statements. The audit report confirms that the company has not incurred any cash losses in the current financial year, compared to a cash loss of ₹6.16 lakh in the preceding year. The board also approved the recommendation of a dividend, if any, subject to the approval of shareholders. The disclosure was made in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Historical Stock Returns for Prism Medico & Pharmacy

1 Day5 Days1 Month6 Months1 Year5 Years
+2.96%-0.70%-3.75%+47.57%+91.84%+232.94%

What specific strategies drove the nearly fourfold increase in revenue from operations?

Can the company sustain this rapid revenue growth and profitability into FY27?

Will the board recommend a dividend payout given the return to profitability?

Prism Medico & Pharmacy
View Company Insights
View All News
like18
dislike

Prism Medico & Pharmacy Appoints Mr. Harpreet Singh as Internal Auditor for FY 2025-2026

2 min read     Updated on 11 May 2026, 07:41 PM
scanx
Reviewed by
Suketu GScanX News Team
AI Summary

Prism Medico & Pharmacy Limited's Board of Directors, at their meeting held on May 11, 2026, approved the appointment of Mr. Harpreet Singh of M/s. S Harpreet and Associates, Chartered Accountants, as internal auditor for the financial year 2025-2026. The board meeting commenced at 04:00 P.M. and concluded at 04:30 P.M. The disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Mr. Harpreet Singh, who has been in practice since 2018, is an associate member of the Institute of Chartered Accountants of India with expertise in direct tax, assurance, and accounting.

powered bylight_fuzz_icon
40054306

*this image is generated using AI for illustrative purposes only.

Prism Medico & Pharmacy Limited has announced the appointment of Mr. Harpreet Singh of M/s. S Harpreet and Associates, Chartered Accountants, as its internal auditor for the financial year 2025-2026. The decision was taken at a Board of Directors meeting held on May 11, 2026, and disclosed to the stock exchanges pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Board Meeting Details

The board meeting during which the appointment was approved was held at the company's registered office located at Suketi Road, Kala Amb, Sirmaur, Himachal Pradesh. The key details of the meeting and the appointment are summarised below:

Parameter: Details
Meeting Date: May 11, 2026
Meeting Commencement: 04:00 P.M.
Meeting Conclusion: 04:30 P.M.
Appointment: Internal Auditor
Appointee: Mr. Harpreet Singh
Firm Name: M/s. S Harpreet and Associates, Chartered Accountants
Applicable Period: Financial Year 2025-2026
Regulatory Disclosure: Regulation 30, SEBI (LODR) Regulations, 2015

The disclosure was signed by Davender Singh, Director (DIN: 09447213) of Prism Medico & Pharmacy Limited.

About the Appointed Auditor

Mr. Harpreet Singh is the proprietor of M/s. S Harpreet and Associates, Chartered Accountants, based in Derabassi, Punjab. He is a graduate and an associate member of the Institute of Chartered Accountants of India and has been in practice since 2018. The firm itself was established in 2019.

Mr. Harpreet Singh's areas of expertise include:

  • Direct Tax
  • Assurance and Accounting
  • Internal Audits and Risk-Based Management Audits
  • Tax Strategy and Compliance

About M/s. S Harpreet and Associates

M/s. S Harpreet and Associates offers a broad range of professional services to domestic and global businesses. The firm's service portfolio spans multiple disciplines, as outlined below:

Service Area: Key Offerings
Audit and Assurance: Statutory Audits, Tax Audits, Internal Audits, Inspection and Investigation Audits
Tax and Regulatory: Tax Planning, Compliance, Representation, International Taxation, Transfer Pricing
Indirect Tax: GST Advisory, Custom-related Advisory Services
Corporate Law Services: Incorporation, Statutory Filings, Corporate Litigation Support
Finance and Accounting Outsourcing: Accounting Processes, Client Reporting
Corporate Finance: Fund Raising, Business Valuation, Intangible Valuation

The firm emphasises core values including integrity, competence, professionalism, responsibility and accountability, simplicity, adaptability, and versatility in its service delivery.

Historical Stock Returns for Prism Medico & Pharmacy

1 Day5 Days1 Month6 Months1 Year5 Years
+2.96%-0.70%-3.75%+47.57%+91.84%+232.94%

How might the appointment of a relatively young firm (established 2019) as internal auditor impact investor confidence in Prism Medico & Pharmacy's governance standards compared to industry peers?

Could this internal audit appointment signal Prism Medico & Pharmacy's preparation for a broader compliance overhaul or potential fundraising activity in the near future?

What are the potential risks to Prism Medico & Pharmacy if M/s. S Harpreet and Associates, given its limited operational history, identifies significant internal control weaknesses during FY 2025-2026?

Prism Medico & Pharmacy
View Company Insights
View All News
like16
dislike

More News on Prism Medico & Pharmacy

1 Year Returns:+91.84%